DASATINIB
dasatinib 100 mg tablet, 30
DASATINIB (9343R)
9343R
Manner of administration:Oral
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Initial treatment
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Continuing treatment
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Induction and Consolidation therapy
Restriction
Indication: Acute lymphoblastic leukaemia
Treatment phase: Maintenance of first complete remission
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $421.56 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||